tweetindex
IT

Celine Halioua

@celinehalioua · San Francisco, CA · joined 27 Sep 2017

Founder + CEO @loyalfordogs 🐶 Working on aging drugs! Longevity Fund, @UniofOxford health econ, @UTAustin neuroscience. Write to learn things.

33 981Followers
2 913Following
6 444Posts total
274KViews on collected posts

Ultimi post

@celinehalioua @adamnash Please medium dogs 💜 1.4K views · 12 likes · 0 reposts · 1 replies Open on X →
read more: https://t.co/C5bwtch7Jc 2.5K views · 29 likes · 1 reposts · 0 replies Open on X →
When we started Loyal there was no FDA pathway for a any lifespan extension drug. Today the FDA accepted our third one! LOY-003, our daily pill for helping large dogs live longer (and healthier) lives, has earned RXE efficacy approval. https://t.co/bqAIXdiBro
4:40
98K views · 820 likes · 82 reposts · 73 replies Open on X →
blissfully unaware of p(doom) https://t.co/4qfYQFQ8bf
69.3K views · 3.4K likes · 74 reposts · 12 replies Open on X →
which should i write this weekend 1 - disease is deviation from optimal biological function 2 - aging thesis 101 3 - the loyal master plan 1.8K views · 8 likes · 1 reposts · 4 replies Open on X →
so is this a good or bad time to mention that i once got three cavities drilled without novocaine 8.2K views · 89 likes · 0 reposts · 14 replies Open on X →
my semi-toxic motto is "be embarassed of yourself six months ago" 4.4K views · 70 likes · 2 reposts · 2 replies Open on X →
@celinehalioua <3 258 views · 5 likes · 0 reposts · 0 replies Open on X →
so unbelievably proud of the loyal team - from crazy idea to execution save the dogs save the world ❤️ read our Director of Veterinary Medicine @SkeptVet's blog here: https://t.co/sBJIBuGbh5 1.4K views · 23 likes · 0 reposts · 2 replies Open on X →
RXE efficacy was the most technically challenging FDA approval to earn, but safety is arguably the most important LOY-002 will be prescribed to keep older dogs healthy, longer - so even rare safety issues are unacceptable 1.8K views · 35 likes · 1 reposts · 1 replies Open on X →
Our safety studies showed no clinically significant side effects, even at 5X the intended longevity dose & an interim analysis of our lifespan extension pivotal trial did not observe a higher rate of clinically-significant side effects in the dogs on LOY-002 vs the placebo 1.6K views · 31 likes · 0 reposts · 1 replies Open on X →
(we cannot share the primary data until approval sadly) With this milestone, the "only" outstanding work to launch LOY-002 is earning the FDA manufacturing (CMC) approval, and continue running our longevity clinical trial excellently. 1.5K views · 20 likes · 0 reposts · 1 replies Open on X →
our dog longevity drug LOY-002 has earned FDA safety approval we now have 2 of 3 major sections of our New Animal Drug Application complete (!) if (when) we earn FDA manufacturing approval, Loyal will launch the *first FDA-approved lifespan extension drug* https://t.co/SBx18e9
82K views · 541 likes · 78 reposts · 43 replies Open on X →

Rispetto ad account della stessa dimensione

7 post degli ultimi 90 giorni, accanto alla fascia di 10K–100K follower. arriva a molti, ma pochi di loro reagiscono.

Visualizzazioni mediane4 419questo account1 015mediana per 10K–100K
Copertura, %13.00%questo account3.77%mediana per 10K–100K
Interazione, %1.22%questo account1.67%mediana per 10K–100K
MetricaQuesto accountMediana per 10K–100KRapporto
Visualizzazioni mediane per post4 4191 0154.35×
Copertura (visualizzazioni ÷ follower)13.00%3.77%3.45×
Tasso di interazione1.22%1.67%0.73×

Altri account di questa fascia →   Confronta con un altro account →   Come sono costruiti questi parametri →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

82K13 Jan
1.5K
1.6K
1.8K
1.4K
258
4.4K30 Aug
8.2K31 Aug
1.8K9 Sep
69.3K13 Sep
98K16 Sep
2.5K
1.4K

Last 13 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.81%13 Jan
1.41%
2.06%
2.10%
1.81%
1.94%
1.67%30 Aug
1.26%31 Aug
0.73%9 Sep
5.01%13 Sep
1.03%16 Sep
1.22%
0.90%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.67%.

What the audience does

Likes87.6%5 069 in total
Reposts4.1%239 in total
Replies2.7%154 in total
Quotes0.6%33 in total
Bookmarks5.0%291 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

Followers by day

14 Sep

Daily snapshots since 14 Sep 2026; the dashed line is the starting count.

Account simili